Top Clinical Trials companies in Hong Kong by EBITDA Margin
Hong Kong
# |
Name |
EBITDA Margin |
Reported Date | Stock Price |
Change |
Price (30 days) | Country |
|---|---|---|---|---|---|---|---|
| 1 |
18.33%
|
Dec. 31, 2023 | USD 0.15 | -0.79% |
|
Hong Kong |
|
| 2 |
17.32%
|
Dec. 31, 2023 | USD 0.21 | -2.31% |
|
Hong Kong |
|
| 3 |
8.03%
|
Dec. 31, 2023 | USD 2.69 | -5.38% |
|
Hong Kong |
|
| 4 |
-220.29%
|
Dec. 31, 2023 | USD 5.25 | -2.96% |
|
Hong Kong |
|
| 5 |
-18,227.20%
|
Dec. 31, 2023 | USD 0.34 | -11.75% |
|
Hong Kong |
Frequently Asked Questions
-
Which Clinical Trials company in Hong Kong has the highest EBITDA Margin ?
The Clinical Trials company in Hong Kong with the highest EBITDA Margin is Lee's Pharmaceutical Holdings Limited (HKSE: 0950.HK) at 18.33%.
-
Which Clinical Trials company in Hong Kong has the lowest EBITDA Margin ?
The Clinical Trials company in Hong Kong with the lowest EBITDA Margin is Sirnaomics Ltd. (HKSE: 2257.HK) at -18,227.20%.
-
What are the top 10 Clinical Trials companies in Hong Kong by EBITDA Margin ?
The top 10 Clinical Trials companies in Hong Kong by EBITDA Margin are Lee's Pharmaceutical Holdings Limited, Frontage Holdings Corporation, HUTCHMED (China) Limited, Prenetics Global Limited and Sirnaomics Ltd..
-
What are the bottom 10 Clinical Trials companies in Hong Kong by EBITDA Margin ?
The bottom 10 Clinical Trials companies in Hong Kong by EBITDA Margin are Sirnaomics Ltd., Prenetics Global Limited, HUTCHMED (China) Limited, Frontage Holdings Corporation and Lee's Pharmaceutical Holdings Limited.
